Black Diamond Therapeutics Inc
$ 2.87
7.89%
15 Apr - close price
- Market Cap 164,419,000 USD
- Current Price $ 2.87
- High / Low $ 2.87 / 2.66
- Stock P/E 7.36
- Book Value 1.96
- EPS 0.39
- Next Earning Report 2026-05-11
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.09 %
- ROE 0.23 %
- 52 Week High 4.94
- 52 Week Low 1.39
About
Black Diamond Therapeutics, Inc., a biotechnology company, discovers and develops small molecule tumor agnostic therapies. The company is headquartered in Cambridge, Massachusetts.
Analyst Target Price
$9.71
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-18 | 2025-11-06 | 2025-08-07 | 2025-05-07 | 2025-03-10 | 2024-11-04 | 2024-08-06 | 2024-05-09 | 2024-03-12 | 2023-11-06 | 2023-08-11 | 2023-05-09 |
| Reported EPS | -0.1361 | -0.15 | -0.19 | 0.98 | -0.28 | -0.2753 | -0.36 | -0.35 | -0.34 | -0.45 | -0.52 | -0.57 |
| Estimated EPS | -0.1746 | -0.235 | -0.2467 | -0.255 | -0.3117 | -0.37 | -0.39 | -0.43 | -0.47 | -0.49 | -0.54 | -0.61 |
| Surprise | 0.0385 | 0.085 | 0.0567 | 1.235 | 0.0317 | 0.0947 | 0.03 | 0.08 | 0.13 | 0.04 | 0.02 | 0.04 |
| Surprise Percentage | 22.0504% | 36.1702% | 22.9834% | 484.3137% | 10.17% | 25.5946% | 7.6923% | 18.6047% | 27.6596% | 8.1633% | 3.7037% | 6.5574% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-11 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.18 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: BDTX
2026-04-16 07:10:14
This article discusses the reasons behind Black Diamond (BDTX) stock's 19.3% increase since its last earnings report. It identifies key factors such as strong financial results, positive analyst sentiment, and promising company developments as drivers for the significant price appreciation. The analysis aims to provide insight into the specific catalysts that have influenced investor confidence in BDTX.
2026-04-15 00:39:43
Wedbush maintains an Outperform rating and $17 price target for Black Diamond Therapeutics (BDTX) after the company reported positive preclinical data for Silevertinib, which shows promise for treating multiple EGFR mutant non-small cell lung cancers. The analyst noted that Silevertinib's unique mechanism could overcome resistance issues seen with other EGFR inhibitors, positioning BDTX for potential growth and M&A interest.
2026-04-13 00:39:02
Black Diamond Therapeutics (NASDAQ:BDTX) has received a "Moderate Buy" consensus rating from eight analysts, with an average 12-month target price of $9.83. The company recently reported Q1 EPS of -$0.14, beating estimates, and institutions hold about 95.47% of its stock. Shares opened at $2.56, with a market capitalization of $146.66 million.
2026-04-12 07:38:49
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month target price of $9.83. This rating reflects cautious optimism regarding the biotech company's pipeline of precision oncology treatments. Several brokerages have adjusted their price targets and ratings, indicating ongoing scrutiny of BDTX stock and its performance.
2026-04-10 11:09:01
Black Diamond Therapeutics (BDTX) is banking on its single asset, silevertinib, a fourth-generation EGFR inhibitor for EGFR-mutant NSCLC. The company highlights its broad activity against various EGFR mutations, strong CNS responses, and consistent safety profile, with critical updates expected in 2026. The stock's future hinges on clinical execution, regulatory progress, and securing late-stage partnerships, as it faces competition from established players like AstraZeneca and Johnson & Johnson.
2026-04-09 17:10:15
Black Diamond Therapeutics (BDTX) is focusing its growth strategy on silevertinib, a next-generation EGFR inhibitor for non-small cell lung cancer (NSCLC) that can cross the blood-brain barrier. Early data shows broad mutation coverage and strong CNS efficacy, addressing critical unmet needs, especially the C797S resistance mutation. While the company's valuation is tied to silevertinib's clinical success and partnerships, it faces intense competition and relies heavily on future regulatory approvals and commercialization.
